Exact Sciences Corp
EXAS: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $53.00 | Fnv | Yjpbpwhw |
Exact Sciences' Cancer Screening Foothold Is Strong, but Liquid Biopsy Pipeline Not Derisked Yet
/s3.amazonaws.com/arc-authors/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
Business Strategy and Outlook
Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype Dx, its tissue-based genomic profiling platform with widespread use in breast cancer. It has a promising pipeline in the nascent liquid biopsy market, including a tissue-informed molecular residual disease, or MRD, test, a blood-based CRC screening test, and a multicancer early detection, or MCED, test.